Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents
-
Narrated by:
-
By:
About this listen
Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.
Related Content:
- Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
activate_mytile_page_redirect_t1
What listeners say about Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.